Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
ASH 2024 preview – multiple myeloma in focus
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
